PMID- 26871512
OWN - NLM
STAT- MEDLINE
DCOM- 20161109
LR  - 20190221
IS  - 2167-9436 (Electronic)
IS  - 2167-9436 (Linking)
VI  - 35
IP  - 1
DP  - 2016 Feb
TI  - Analysis of aDR5scFv with Specific Identification and Function.
PG  - 25-31
LID - 10.1089/mab.2015.0030 [doi]
AB  - Death receptor 5 (DR5) can selectively induce cell death in a wide variety of 
      tumor cells. However, at least certain versions of the recombinant soluble TRAIL 
      (sTRAIL) or anti-DR5 monoclonal antibody (mAb) are also shown to cause apoptosis 
      in normal cells (especially in hepatocytes), hampering its clinical use for 
      cancer therapy. Recently, the development of small recombinant antibody fragments 
      as high-affinity therapeutic reagents with reduced immunogenicity has come under 
      the spotlight. A popular format of engineered recombinant antibody fragment is 
      the single-chain fixed-variable (scFv) molecule, in which the VH and VL regions 
      of the parental antibody are joined by a polypeptide linker. The scFv fragment 
      retains the target specificity and antigen binding affinity of the intact 
      antibody, whereas it can be genetically designed and produced in large quantities 
      by ectopically expressing both VH and VL regions from a single cDNA in cells. In 
      this study, an aDR5scFv was constructed and expressed, and it was conformed so 
      that it could recognize and bind eDR5 specifically. The therapeutic effects on 
      human lung adenocarcinoma cells lines 973 in vitro and in vivo were detected by 
      MTT assay, flow cytometry, hematoxylin and eosin staining, and TUNEL assay. 
      aDR5scFv was able to induce 973 cell apoptosis in an in vitro system. The protein 
      expressions of caspase-3, Bax, and cytochrome c were raised, and aDR5scFv also 
      inhibited tumor growth in mice with its effect as well as with radiotherapy. It 
      is concluded that aDR5scFv could possibly be considered as a novel therapeutic 
      candidate for the treatment of tumors.
FAU - Cheng, Xiaofeng
AU  - Cheng X
AD  - 1 Radiotherapy Department, ChengGong Hospital, Xiamen University , Xiamen, 
      Fujian, China .
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Meng, Qingyu
AU  - Meng Q
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Gao, Chunling
AU  - Gao C
AD  - 1 Radiotherapy Department, ChengGong Hospital, Xiamen University , Xiamen, 
      Fujian, China .
FAU - Zhuang, Guohong
AU  - Zhuang G
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Huang, Xiaoping
AU  - Huang X
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Zhang, Jiakai
AU  - Zhang J
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Liu, Bin
AU  - Liu B
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Fan, Xin
AU  - Fan X
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
FAU - Zhang, Minping
AU  - Zhang M
AD  - 2 Center of Anti-Cancer Research, Medical College of Xiamen University , Xiamen, 
      Fujian, China .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Monoclon Antib Immunodiagn Immunother
JT  - Monoclonal antibodies in immunodiagnosis and immunotherapy
JID - 101590955
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoglobulin Variable Region)
RN  - 0 (Receptors, TNF-Related Apoptosis-Inducing Ligand)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Single-Chain Antibodies)
RN  - 0 (TNFRSF10B protein, human)
SB  - IM
MH  - Adenocarcinoma/drug therapy/pathology/radiotherapy
MH  - Adenocarcinoma of Lung
MH  - Animals
MH  - Antibodies, Monoclonal/genetics/immunology/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/drug effects
MH  - Cell Line, Tumor
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunoglobulin Variable Region/genetics/immunology
MH  - Lung Neoplasms/drug therapy/pathology/radiotherapy
MH  - Mice, Nude
MH  - Receptors, TNF-Related Apoptosis-Inducing Ligand/*immunology
MH  - Recombinant Proteins/genetics/immunology/*pharmacology
MH  - Single-Chain Antibodies/genetics/immunology
MH  - Xenograft Model Antitumor Assays
EDAT- 2016/02/13 06:00
MHDA- 2016/11/10 06:00
CRDT- 2016/02/13 06:00
PHST- 2016/02/13 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2016/11/10 06:00 [medline]
AID - 10.1089/mab.2015.0030 [doi]
PST - ppublish
SO  - Monoclon Antib Immunodiagn Immunother. 2016 Feb;35(1):25-31. doi: 
      10.1089/mab.2015.0030.